Thursday 30th July 2020
|Text too small?|
AFT Pharmaceuticals (NZX.AFT, ASX.AFP) has signed an exclusive Maxigesic IV® licensing and supply agreement for Bulgaria, Cyprus, the Czech Republic, Hungary, Romania and Slovakia, countries with a combined population of more than 53 million*.
The agreement is with the Cyprus based multinational pharmaceutical company, Medochemie, which earlier this year signed a licensing agreement for Maxigesic IV® for Ukraine and the nine countries of the Commonwealth of Independent States.
AFT Pharmaceutical’s Managing Director Dr Hartley Atkinson says: “We are delighted to further strengthen our partnership with Medochemie. It is a strong, dynamic partner in this region and its business teams have an excellent understanding of their local markets.”
Maxigesic IV® regulatory approvals in the six European countries covered by this agreement are expected to conclude in the next few months, with sales then expected in the 2021calendar year.
Maxigesic IV® (Paracetamol 1000mg+ Ibuprofen 300mg solution for infusion) is an intravenous formulation developed as a line extension to Maxigesic tablets, for use post-operatively in hospitals when patients cannot take a medicine orally.
A major Phase 3 clinical trial conducted in the USA found that Maxigesic IV provided significantly better pain relief than either paracetamol (acetaminophen) IV or ibuprofen IV alone in the same doses.**
Following on from the registration of Maxigesic IV® in Australia and New Zealand in mid-2019, AFT has now licensed the medication in more than 90 countries. Meanwhile, the tablet form of Maxigesic has been licensed in more than 125 countries
* 2019 population. Source: Statista, 2020
**Daniels, S.E, Playne, R., Stanescu, I., Zhang, J., Gottlieb, I.J, Atkinson, H.C. (2019). Efficacy and safety of an intravenous acetaminophen/ibuprofen fixed-dose combination after bunionectomy: A randomized, double-blind, factorial, placebo- controlled trial. Clinical Therapeutics 41 (10): 1982-1995. Research sponsored by AFT Pharmaceuticals.
Source: AFT Pharmaceuticals (NZX.AFT, ASX.AFP)
No comments yet
Kathmandu Holdings Limited announces Annual Report 2020
Genesis Energy announced its FY21 Q1 Performance Report
Vector announces its operational performance for the 3 months
Abano Scheme Meeting Materials
Westpac and Afterpay announce partnership
NWF agrees a new Variable Volume Fixed Price Agreement
Takeovers Panel states no objection to Metlifecare scheme
Sichuan Province Trial Confirms Truscreen Technology
PEB Announces Executive Team Changes to Support Growth
Sylvia Park opens the doors on its new Level 1 expansion